Report by Anti-340B Group Presents Erroneous Picture

by Admin | September 14, 2021 1:22 pm

Sept. 14, 2021– New Report misses the mark.A new report[1] issued by the Community Oncology Alliance (COA) claims 340B hospitals “charge both commercial payers and uninsured patients extraordinarily high prices and use an aggressive form of price discrimination between payers.” However, the report is highly flawed and presents an inaccurate picture of the role 340B plays in America’s health care safety net.

COA commissioned Moto Bioadvisors to review how much 340B hospitals pay for cancer drugs and the amount they are reimbursed by third-party payers. COA is a longtime, vocal critic of the 340B program and participating hospitals. The report makes numerous errors that render the results inaccurate:

When these types of reports find their way into the public dialogue over the 340B program, they obscure the tremendous good the program does for the health care safety net and the patients it serves. Policymakers who understand the benefits and intent of the program will recognize the holes in these arguments.

  1. report:
  2. findings:
  3. low-incomes:
  4. racially diverse:

Source URL: